AURA
Aura Biosciences, Inc.
Price Chart
Latest Quote
$6.47
+0.19 (+3.03%)
Current Price
| Previous Close | $6.28 |
| Open | $6.25 |
| Day High | $6.53 |
| Day Low | $6.25 |
| Volume | 171,186 |
Stock Information
| Shares Outstanding | 103.39M |
| Total Debt | $16.99M |
| Cash Equivalents | $114.73M |
| Net Income | $-112.39M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $668.91M |
| EPS (TTM) | $-1.71 |
| Exchange | NGM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $551.53M |
| Income | $-112.39M |
| Book/sh | $1.67 |
| Cash/sh | $1.11 |
| Employees | 113 |
Financial Ratios
| Quick Ratio | 6.87 |
| Current Ratio | 7.09 |
| Debt/Eq | 15.84 |
Returns & Margins
| ROA | -50.59% |
| ROE | -95.57% |
Ownership
| Insider Ownership | 1.01% |
| Institutional Ownership | 51.03% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -3.19 |
| P/B | 3.87 |
Analyst Data
| Recommendation | none |
| Target Price | $18.80 |
Technical Indicators
| SMA20 | $6.96 |
| SMA50 | $7.25 |
| SMA200 | $6.25 |
| RSI | 18.52 |
| ATR | 0.3336 |
| Shares Float | 93.38M |
| Short Float | 4.37% |
| Short Ratio | 4.69 |
| Volatility | 0.39 |
| Rel Volume | 0.36 |
Performance History
| Week | +1.89% |
| Month | -16.41% |
| Quarter | -4.99% |
| 6 Months | -1.07% |
| YTD | +22.08% |
| Year | +0.78% |
| 3 Years | -48.16% |
| 10 Years | -56.28% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-17 | $6.47 | 171,186 |
| 2026-06-15 | $6.45 | 581,900 |
| 2026-06-12 | $6.41 | 959,100 |
| 2026-06-11 | $6.21 | 816,600 |
| 2026-06-10 | $6.12 | 676,700 |
| 2026-06-09 | $6.35 | 647,500 |
| 2026-06-08 | $6.48 | 248,400 |
| 2026-06-05 | $6.63 | 347,100 |
| 2026-06-04 | $6.80 | 492,000 |
| 2026-06-03 | $6.88 | 253,200 |
| 2026-06-02 | $6.90 | 480,000 |
| 2026-06-01 | $7.19 | 343,000 |
| 2026-05-29 | $7.47 | 439,000 |
| 2026-05-28 | $7.50 | 339,900 |
| 2026-05-27 | $7.66 | 266,900 |
| 2026-05-26 | $7.61 | 276,800 |
| 2026-05-22 | $7.60 | 278,200 |
| 2026-05-21 | $7.65 | 898,700 |
| 2026-05-20 | $7.47 | 486,300 |
| 2026-05-19 | $7.39 | 555,400 |
| 2026-05-18 | $7.47 | 1,010,500 |
About Aura Biosciences, Inc.
Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision therapies to treat solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates. Its lead candidate is bel-sar, which is in late-stage clinical development for the treatment of patients with primary choroidal melanoma and other ocular oncology indications, as well as in early-stage clinical development in bladder cancer. It focuses on assessing the safety and efficacy of bel-sar in treating a range of other solid tumors, including bladder cancer. The company was incorporated in 2009 and is headquartered in Boston, Massachusetts.
đ° Latest News
Aura Biosciences Gears Up for Bel-Sar Filing as Pivotal Eye Cancer Trial Advances
MarketBeat âĸ 2026-05-27T20:04:57Z
Aura Biosciences Highlights Bel-Sar Eye Cancer Strategy, Mid-Year Bladder Data
MarketBeat âĸ 2026-05-20T02:02:22Z
Are Medical Stocks Lagging Aura Biosciences (AURA) This Year?
Zacks âĸ 2026-04-22T13:40:02Z
Does Aura Biosciences (AURA) Have the Potential to Rally 179.84% as Wall Street Analysts Expect?
Zacks âĸ 2026-04-20T13:55:03Z
Aura Biosciences, Inc. (AURA) Just Flashed Golden Cross Signal: Do You Buy?
Zacks âĸ 2026-04-10T13:55:02Z
Is Aura Biosciences (AURA) Stock Outpacing Its Medical Peers This Year?
Zacks âĸ 2026-04-06T13:40:02Z
Wall Street Analysts Predict a 201.49% Upside in Aura Biosciences (AURA): Here's What You Should Know
Zacks âĸ 2026-04-02T13:55:03Z
Is Aura Biosciences (AURA) Outperforming Other Medical Stocks This Year?
Zacks âĸ 2026-03-20T13:40:04Z
Aura Biosciences Eyes Phase 3 Enrollment Milestone, Reaffirms Q4 2027 Melanoma Data Timeline
MarketBeat âĸ 2026-03-11T10:48:01Z
Aura Biosciences Touts Phase 3 bel-sar Momentum, Eyes Mid-Year Bladder Cancer Data at TD Cowen Conference
MarketBeat âĸ 2026-03-05T06:33:03Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $0 | $0 | $0 | $0 |
| Operating Revenue | $0 | $0 | $0 | $0 |
| Expenses | ||||
| Total Expenses | $112,791,000 | $96,116,000 | $84,991,000 | $60,295,000 |
| Other Income Expense | $77,000 | $-120,000 | $132,000 | $-332,000 |
| Other Non Operating Income Expenses | $77,000 | $-120,000 | $-76,000 | $-14,000 |
| Net Non Operating Interest Income Expense | $6,631,000 | $9,429,000 | $8,588,000 | $1,864,000 |
| Operating Expense | $112,791,000 | $96,116,000 | $84,991,000 | $60,295,000 |
| General And Administrative Expense | $22,491,000 | $22,814,000 | $19,759,000 | $18,057,000 |
| Total Other Finance Cost | - | - | - | - |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-106,191,000 | $-86,919,000 | $-76,408,000 | $-58,763,000 |
| Net Interest Income | $6,631,000 | $9,429,000 | $8,588,000 | $1,864,000 |
| Interest Income | $6,631,000 | $9,429,000 | $8,588,000 | $1,864,000 |
| Normalized Income | $-106,191,000 | $-86,919,000 | $-76,616,000 | $-58,445,000 |
| Net Income From Continuing And Discontinued Operation | $-106,191,000 | $-86,919,000 | $-76,408,000 | $-58,763,000 |
| Total Operating Income As Reported | $-112,791,000 | $-96,116,000 | $-84,991,000 | $-60,295,000 |
| Net Income Common Stockholders | $-106,191,000 | $-86,919,000 | $-76,408,000 | $-58,763,000 |
| Net Income | $-106,191,000 | $-86,919,000 | $-76,408,000 | $-58,763,000 |
| Net Income Including Noncontrolling Interests | $-106,191,000 | $-86,919,000 | $-76,408,000 | $-58,763,000 |
| Net Income Continuous Operations | $-106,191,000 | $-86,919,000 | $-76,408,000 | $-58,763,000 |
| Pretax Income | $-106,083,000 | $-86,807,000 | $-76,271,000 | $-58,763,000 |
| Interest Income Non Operating | $6,631,000 | $9,429,000 | $8,588,000 | $1,864,000 |
| Operating Income | $-112,791,000 | $-96,116,000 | $-84,991,000 | $-60,295,000 |
| Special Income Charges | - | $0 | $208,000 | $-318,000 |
| Per Share | ||||
| Diluted EPS | $-1.76 | $-1.75 | $-1.93 | $-1.96 |
| Basic EPS | $-1.76 | $-1.75 | $-1.93 | $-1.96 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-111,662,000 | $-94,893,000 | $-83,904,000 | $-58,800,000 |
| Reconciled Depreciation | $1,129,000 | $1,223,000 | $1,295,000 | $1,177,000 |
| EBITDA (Bullshit earnings) | $-111,662,000 | $-94,893,000 | $-83,696,000 | $-59,118,000 |
| EBIT | $-112,791,000 | $-96,116,000 | $-84,991,000 | $-60,295,000 |
| Diluted Average Shares | $60,337,608 | $49,650,480 | $39,620,036 | $29,937,228 |
| Basic Average Shares | $60,337,608 | $49,650,480 | $39,620,036 | $29,937,228 |
| Diluted NI Availto Com Stockholders | $-106,191,000 | $-86,919,000 | $-76,408,000 | $-58,763,000 |
| Tax Provision | $108,000 | $112,000 | $137,000 | $0 |
| Research And Development | $90,300,000 | $73,302,000 | $65,232,000 | $42,238,000 |
| Selling General And Administration | $22,491,000 | $22,814,000 | $19,759,000 | $18,057,000 |
| Other Gand A | $22,491,000 | $22,814,000 | $19,759,000 | $18,057,000 |
| Total Unusual Items | - | $0 | $208,000 | $-318,000 |
| Total Unusual Items Excluding Goodwill | - | $0 | $208,000 | $-318,000 |
| Gain On Sale Of Ppe | - | $0 | $208,000 | $-318,000 |
| Gain On Sale Of Security | - | - | - | $-9,000 |
| Preferred Stock Dividends | - | - | - | - |
Fetched: 2026-06-14
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $136,913,000 | $151,970,000 | $225,848,000 | $195,583,000 |
| Total Assets | $169,430,000 | $182,503,000 | $255,075,000 | $223,935,000 |
| Total Non Current Assets | $19,691,000 | $21,880,000 | $23,281,000 | $27,233,000 |
| Other Non Current Assets | $1,239,000 | $1,286,000 | $1,277,000 | $1,191,000 |
| Current Assets | $149,739,000 | $160,623,000 | $231,794,000 | $196,702,000 |
| Other Current Assets | $1,175,000 | $1,826,000 | $2,409,000 | $715,000 |
| Prepaid Assets | $4,323,000 | $7,703,000 | $3,216,000 | $7,156,000 |
| Cash Cash Equivalents And Short Term Investments | $144,241,000 | $151,094,000 | $226,150,000 | $188,811,000 |
| Cash And Cash Equivalents | $59,515,000 | $31,693,000 | $41,063,000 | $121,582,000 |
| Restricted Cash | - | $0 | $19,000 | $20,000 |
| Debt | ||||
| Total Debt | $17,377,000 | $18,769,000 | $19,557,000 | $20,858,000 |
| Long Term Debt And Capital Lease Obligation | $14,134,000 | $15,620,000 | $16,870,000 | $17,895,000 |
| Current Debt And Capital Lease Obligation | $3,243,000 | $3,149,000 | $2,687,000 | $2,963,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $32,517,000 | $30,533,000 | $29,227,000 | $28,352,000 |
| Total Non Current Liabilities Net Minority Interest | $14,134,000 | $15,620,000 | $16,870,000 | $17,895,000 |
| Current Liabilities | $18,383,000 | $14,913,000 | $12,357,000 | $10,457,000 |
| Other Current Liabilities | $242,000 | $188,000 | $935,000 | $325,000 |
| Payables And Accrued Expenses | $8,893,000 | $6,120,000 | $5,232,000 | $4,464,000 |
| Payables | $1,549,000 | $2,304,000 | $1,787,000 | $2,921,000 |
| Accounts Payable | $1,549,000 | $2,304,000 | $1,787,000 | $2,921,000 |
| Derivative Product Liabilities | - | - | - | - |
| Non Current Deferred Liabilities | - | - | - | - |
| Equity | ||||
| Common Stock Equity | $136,913,000 | $151,970,000 | $225,848,000 | $195,583,000 |
| Total Equity Gross Minority Interest | $136,913,000 | $151,970,000 | $225,848,000 | $195,583,000 |
| Stockholders Equity | $136,913,000 | $151,970,000 | $225,848,000 | $195,583,000 |
| Gains Losses Not Affecting Retained Earnings | $-102,000 | $263,000 | $539,000 | $-72,000 |
| Other Equity Adjustments | $-102,000 | $263,000 | $539,000 | $-72,000 |
| Retained Earnings | $-480,418,000 | $-374,227,000 | $-287,308,000 | $-210,900,000 |
| Other | ||||
| Ordinary Shares Number | $63,587,777 | $49,998,279 | $49,350,788 | $37,771,918 |
| Share Issued | $63,587,777 | $49,998,279 | $49,350,788 | $37,771,918 |
| Tangible Book Value | $136,913,000 | $151,970,000 | $225,848,000 | $195,583,000 |
| Invested Capital | $136,913,000 | $151,970,000 | $225,848,000 | $195,583,000 |
| Working Capital | $131,356,000 | $145,710,000 | $219,437,000 | $186,245,000 |
| Capital Lease Obligations | $17,377,000 | $18,769,000 | $19,557,000 | $20,858,000 |
| Total Capitalization | $136,913,000 | $151,970,000 | $225,848,000 | $195,583,000 |
| Additional Paid In Capital | $617,433,000 | $525,934,000 | $512,617,000 | $406,555,000 |
| Capital Stock | $0 | $0 | $0 | $0 |
| Common Stock | $0 | $0 | $0 | $0 |
| Long Term Capital Lease Obligation | $14,134,000 | $15,620,000 | $16,870,000 | $17,895,000 |
| Current Capital Lease Obligation | $3,243,000 | $3,149,000 | $2,687,000 | $2,963,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $6,005,000 | $5,456,000 | $3,503,000 | $2,705,000 |
| Current Accrued Expenses | $7,344,000 | $3,816,000 | $3,445,000 | $1,543,000 |
| Net PPE | $18,452,000 | $20,594,000 | $22,004,000 | $26,042,000 |
| Accumulated Depreciation | $-7,052,000 | $-5,986,000 | $-5,036,000 | $-3,864,000 |
| Gross PPE | $25,504,000 | $26,580,000 | $27,040,000 | $29,906,000 |
| Leases | $471,000 | $471,000 | $0 | $0 |
| Construction In Progress | $228,000 | $272,000 | $391,000 | $1,805,000 |
| Other Properties | $24,805,000 | $25,837,000 | $26,649,000 | $28,101,000 |
| Properties | $0 | $0 | $0 | $0 |
| Other Short Term Investments | $84,726,000 | $119,401,000 | $185,087,000 | $67,229,000 |
| Machinery Furniture Equipment | - | - | $289,000 | $133,000 |
| Preferred Stock | - | - | - | - |
Fetched: 2026-06-14
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-85,189,000 | $-81,058,000 | $-64,556,000 | $-55,695,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-84,742,000 | $-79,805,000 | $-63,847,000 | $-54,601,000 |
| Cash Flow From Continuing Operating Activities | $-84,742,000 | $-79,805,000 | $-63,847,000 | $-54,601,000 |
| Operating Gains Losses | - | - | $208,000 | $-22,000 |
| Investing Activities | ||||
| Capital Expenditure | $-447,000 | $-1,253,000 | $-709,000 | $-1,094,000 |
| Investing Cash Flow | $35,595,000 | $68,821,000 | $-113,963,000 | $-67,869,000 |
| Cash Flow From Continuing Investing Activities | $35,595,000 | $68,821,000 | $-113,963,000 | $-67,869,000 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $52,571,000 | $0 | $95,786,000 | $95,199,000 |
| Financing Cash Flow | $77,155,000 | $1,595,000 | $97,290,000 | $95,629,000 |
| Cash Flow From Continuing Financing Activities | $77,155,000 | $1,595,000 | $97,290,000 | $95,629,000 |
| Net Common Stock Issuance | $52,571,000 | $0 | $95,786,000 | $8,549,000 |
| Common Stock Issuance | $52,571,000 | $0 | $95,786,000 | $8,549,000 |
| Net Preferred Stock Issuance | - | - | $92,616,000 | $86,650,000 |
| Preferred Stock Issuance | - | - | $92,616,000 | $86,650,000 |
| Net Other Financing Charges | - | - | - | - |
| Other | ||||
| End Cash Position | $60,283,000 | $32,461,000 | $41,850,000 | $122,370,000 |
| Beginning Cash Position | $32,461,000 | $41,850,000 | $122,370,000 | $149,211,000 |
| Effect Of Exchange Rate Changes | $-186,000 | $0 | - | - |
| Changes In Cash | $28,008,000 | $-9,389,000 | $-80,520,000 | $-26,841,000 |
| Proceeds From Stock Option Exercised | $24,584,000 | $1,595,000 | $1,504,000 | $430,000 |
| Net Investment Purchase And Sale | $36,042,000 | $70,074,000 | $-113,254,000 | $-66,775,000 |
| Sale Of Investment | $120,000,000 | $129,182,000 | $120,397,000 | $53,009,000 |
| Purchase Of Investment | $-83,958,000 | $-59,108,000 | $-233,651,000 | $-119,784,000 |
| Net PPE Purchase And Sale | $-447,000 | $-1,253,000 | $-709,000 | $-1,094,000 |
| Purchase Of PPE | $-447,000 | $-1,253,000 | $-709,000 | $-1,094,000 |
| Change In Working Capital | $5,971,000 | $-2,642,000 | $4,441,000 | $-3,846,000 |
| Change In Other Current Liabilities | $-1,392,000 | $-788,000 | $-1,322,000 | $-744,000 |
| Change In Other Current Assets | $47,000 | $-9,000 | $-86,000 | $-423,000 |
| Change In Payables And Accrued Expense | $3,285,000 | $2,059,000 | $2,270,000 | $574,000 |
| Change In Accrued Expense | $4,131,000 | $1,577,000 | $3,310,000 | $234,000 |
| Change In Payable | $-846,000 | $482,000 | $-1,040,000 | $340,000 |
| Change In Account Payable | $-846,000 | $482,000 | $-1,040,000 | $340,000 |
| Change In Prepaid Assets | $4,031,000 | $-3,904,000 | $3,579,000 | $-3,253,000 |
| Other Non Cash Items | $1,578,000 | $1,470,000 | $1,837,000 | $968,000 |
| Stock Based Compensation | $14,317,000 | $11,722,000 | $8,772,000 | $6,412,000 |
| Amortization Of Securities | $-1,546,000 | $-4,659,000 | $-3,992,000 | $-527,000 |
| Depreciation Amortization Depletion | $1,129,000 | $1,223,000 | $1,295,000 | $1,177,000 |
| Depreciation And Amortization | $1,129,000 | $1,223,000 | $1,295,000 | $1,177,000 |
| Depreciation | $1,129,000 | $1,223,000 | $1,295,000 | $1,177,000 |
| Net Income From Continuing Operations | $-106,191,000 | $-86,919,000 | $-76,408,000 | $-58,763,000 |
| Gain Loss On Sale Of PPE | - | $0 | $208,000 | $-22,000 |
| Gain Loss On Investment Securities | - | - | - | - |
Fetched: 2026-06-14